Key facts
- Bright Uro’s last known valuation is $92.0M (Jun 2025).
- It has raised $47.0M across 2 recorded rounds; the latest was Early Stage VC ($15.0M) in Jun 2025.
- Notable investors include MedTech Innovator, University of California, AIN Ventures, Academy Investor Network, Device of Tomorrow Capital — 11 tracked in total.
- Bright Uro has filed 6 Form Ds with the SEC since 2023, most recently Sep 2025 ($15.0M sold to 35 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Bright Uro
Funding rounds
2 roundsAbout Bright Uro
Developer of a wireless, catheter-free, urodynamic monitoring system designed to improve the diagnosis and management of lower urinary tract symptoms. The company's system offers cloud-based data access and a streamlined digital workflow for enhancing treatment decisions and patient experience by allowing spontaneous voiding in a natural setting, enabling clinicians and patients facing bladder control issues to achieve more accurate and comfortable diagnostic assessments.
- Sector
- Healthcare
- HQ
- Irvine, CA, United States
- Founded
- 2021
- Employees
- 44
- Website
- gleanuds.com/
- Ownership
- Privately Held (backing)
Bright Uro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bright Uro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bright Uro in its N-PORT filings yet. We sweep new filings monthly.